trending Market Intelligence /marketintelligence/en/news-insights/trending/r_xeT16e9naMpXTxjs-y8Q2 content esgSubNav
In This List

US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

The U.S. FDA approved Imbruvica for the treatment of relapsed or refractory marginal zone lymphoma, a rare form of blood cancer.

The drug, which is jointly developed and commercialized by AbbVie Inc.'s Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech Inc., is already approved for patients with mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia blood cancers.